COMMUNIQUÉS West-GlobeNewswire

Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types

02/04/2024 - 12:30

WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tissue Control (ATC) [...]

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

02/04/2024 - 12:18

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug [...]

RadNet Announces Outpatient Radiology Partnership with Providence Health System to Include Seven Centers in Burbank, Santa Clarita and the Northern San Fernando Valley of Los Angeles

02/04/2024 - 12:00

LOS ANGELES, April 02, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, fixed-site outpatient diagnostic imaging services through a network of 366 owned and/or operated [...]

BioPorto A/S to Host Annual Earnings Webcast

02/04/2024 - 10:47

April 2, 2024 News release BioPorto A/S to Host Annual Earnings Webcast COPENHAGEN, DENMARK and BOSTON, MA, USA, April 2, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro [...]

Crossject advances in its U.S. Strategy and reports Financial Results for 2023

02/04/2024 - 10:30

Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDA Expectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE® in Q1 2025 [...]

Crossject poursuit sa stratégie de développement aux États-Unis et publie ses résultats financiers pour 2023

02/04/2024 - 10:30

Amélioration notable de la visibilité sur les perspectives règlementaires et commerciales aux États-Unis depuis les derniers échanges avec la FDA. Attente d’une obtention de l’Autorisation d’Utilisation d’Urgence (EUA) [...]

Transactions in Connection with Share Buy-back Program

02/04/2024 - 09:24

Company Announcement COPENHAGEN, Denmark; April 2, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. [...]

Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.

02/04/2024 - 08:00

COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ® , the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for [...]

BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer

02/04/2024 - 07:54

April 2, 2024 Announcement no. 04 BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer COPENHAGEN, DENMARK and BOSTON, MA, USA, April 2, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or [...]

ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System

02/04/2024 - 07:30

FDA clearance would allow the Company to market its breakthrough therapy to improve or restore hand and arm function after spinal cord injury in the US THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING [...]

OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology

02/04/2024 - 07:30

OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173 [...]

OSE Immunotherapeutics annonce une publication sur CLEC-1, point de contrôle immunitaire innovant, dans la revue à Comité de lecture Journal of Immunology

02/04/2024 - 07:30

OSE Immunotherapeutics annonce une publication sur CLEC-1, point de contrôle immunitaire innovant, dans la revue à Comité de lecture Journal of Immunology Nantes, France, le 2 avril 2024, 7 heures 30 – OSE [...]

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

02/04/2024 - 07:00

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical development STRO-003 targets ROR1, a clinically validated [...]

Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides

02/04/2024 - 07:00

Ipsen obtient les droits mondiaux exclusifs de développement et de commercialisation de STRO-003, un conjugué anticorps-petite molecule en voie de franchir les dernières étapes de développement préclinique. STRO-003 [...]

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

02/04/2024 - 06:30

— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in combination with a leading [...]

Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering

02/04/2024 - 05:00

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an [...]

Interactive Strength Inc. (Nasdaq: TRNR) Reports Fourth Quarter 2023 Results

02/04/2024 - 03:17

Net Loss and Earnings per Diluted Share of $11.4 million and $0.80 Adjusted EBITDA was a $3.5 million loss, a $5.5 million improvement versus fourth quarter of 2022 The Company confirms it expects to be run-rate [...]

ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02/04/2024 - 03:00

Garden City, NY, April 01, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today announced that it has granted [...]

CORRECTION - ACE Venture Enterprises, Inc. Announces Planned Acquisition of Vireo Health of New York from Goodness Growth Holdings

02/04/2024 - 02:52

– Led by Steven Acevedo and Art Isagholian, ACE Venture Enterprises, Inc., a minority-owned business, plans to acquire Vireo Health of New York to accelerate entry into the New York market – – Ace plans to retain [...]